4 Healthcare Stock Stories Deserving a Tuesday Read
Amgen Inc. (NASDAQ:AMGN): Closing price $109.13
On Tuesday, Amgen announced that it will present new data on omecamtiv mecarbil, which is a small molecule cardiac myosin activator that is being evaluated for the treatment of heart failure in conjunction with Cytokinetics. Amgen will also exhibit data on AMG 145, an investigational human monoclonal antibody that inhibits PCSK9, a protein that lowers the liver’s ability to remove low-density lipoprotein cholesterol, or bad cholesterol, from the blood. The firm will present the data at the upcoming ESC Congress 2013, organized by the European Society of Cardiology in Amsterdam.